Madrigal Pharmaceuticals (MDGL) reported strong commercial ramp-up for its MASH therapy, Rezdiffra, driving 9-month (9M) product revenue to \(637.3M (up 730% YoY), with Q3 revenue reaching \)287.3M (US launch began April 2024; EU launch began Sept 2025). Despite significant increases in SG&A and R&D expenses supporting commercialization, the 9M Net Loss narrowed substantially to \(229.7M (vs. \)406.5M prior year), although the Q3 Net Loss widened slightly to $114.2M.
Financing and Capital Structure: The company substantially strengthened its balance sheet, reporting total liquidity of $1.115
...